表紙
市場調査レポート

抗体薬物複合体 (ADC:Antibody Drug Conjugates) 市場:第3版

Antibody Drug Conjugates Market (3rd Edition)

発行 ROOTS ANALYSIS 商品コード 283285
出版日 ページ情報 英文 357 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
抗体薬物複合体 (ADC:Antibody Drug Conjugates) 市場:第3版 Antibody Drug Conjugates Market (3rd Edition)
出版日: 2015年12月10日 ページ情報: 英文 357 Pages
概要

抗体薬物複合体 (ADC:Antibody Drug Conjugates) は現在、ADCETRIS® および KADCYLA® の2薬のみが上市されており、これらの売上を合わせた市場規模は2015年、約9億ドルの規模を記録しました。

当レポートでは、抗体薬物複合体 (ADC) 市場の現状と見通しについて調査し、ADCの概要・メリット、臨床および前臨床パイプラインの動向、ADCの主な適応症、上市予定のADC薬の詳細プロファイルと売上予測、企業間の提携・協力の状況、ベンチャーキャピタルの動き、主要製薬会社のプロファイル、ADC受託製造の例、SWOT分析、専門家へのインタビューなどをまとめています。

第1章 序章

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 概要
  • 癌治療の進化
  • 癌の治療法
    • 外科手術
    • 放射線治療
    • 化学療法
    • 標的治療
  • 癌の治療のためのモノクローナル抗体
  • ADC:重要コンポーネント
    • 抗体
    • サイトトキシン
    • リンカー
  • 従来の治療法をしのぐADCのメリット

第4章 市場概要

  • 概要
  • 臨床パイプライン
    • 開発段階別
    • 開発段階別
    • リンカー別
    • サイトトキシン別
    • 技術プロバイダー別
  • 前臨床パイプライン
    • 開発段階別
    • 開発段階別
    • 地域別

第5章 KOL分析

  • 背景
  • 現在の研究環境
    • ADCETRIS®:KOL
    • KADCYLA®:KOL
    • その他のADC:KOL
  • もっとも著名なKOL

第6章 ADCの主要治療部門

  • 概要
  • 血液悪性腫瘍
    • 白血病・リンパ腫
      • イントロダクション・疫学: 白血病
      • 現在の治療環境
      • 白血病/リンパ腫向けADC
    • 多発性骨髄腫
      • イントロダクション・疫学
      • 現在の治療環境
      • 多発性骨髄腫向けADC
  • 固形癌
    • 転移性黒色腫
      • イントロダクション・疫学
      • 現在の治療環境
      • 転移性黒色腫向けADC
    • 膀胱癌
      • イントロダクション・疫学
      • 現在の治療環境
      • 膀胱癌向けADC
    • 腎臓癌
      • イントロダクション・疫学
      • 現在の治療環境
      • 腎臓癌向けADC
    • 卵巣癌
      • イントロダクション・疫学
      • 現在の治療環境
      • 卵巣癌向けADC
    • 乳癌
      • イントロダクション・疫学
      • 現在の治療環境
      • 乳癌向けADC
    • 膠芽腫
      • イントロダクション・疫学
      • 現在の治療環境
      • 膠芽腫向けADC
    • 肺癌
      • イントロダクション・疫学
      • 現在の治療環境
      • 肺癌向けADC
    • 直腸癌
      • イントロダクション・疫学
      • 現在の市場環境
      • 直腸癌向けADC
    • 前立腺癌
      • イントロダクション・疫学
      • 現在の市場環境
      • 前立腺癌向けADC

第7章 上市予定のADC薬:詳細プロファイル・市場予測

  • 概要
  • 総市場の予測
    • 範囲・制約
    • 予測手法
    • ADC薬の総売上予測
      • ADCタイプ別
      • リンカータイプ別
      • サイトトキシンタイプ別
  • ADCETRIS®/ Brentuximab vedotin (Seattle Genetics / Millennium Pharmaceuticals)
    • 薬剤の概要
    • 作用機序
    • コスト・投与量・償還:ADCETRIS®
    • 高価格の理由
    • 臨床開発
    • 主な臨床試験結果
    • ADCETRIS® 売上の推移
    • 市場拡張戦略
    • ADCETRIS® 売上予測:中期
    • ADCETRIS® 売上予測:長期
  • KADCYLA® / T-DM1 / RG3502 (Genentech / Roche)
    • 薬剤の概要
    • 作用機序
    • コスト・投与量・償還:KADCYLA®
    • 承認の経緯
    • 臨床開発
    • KADCYLA® 売上の推移
    • KADCYLA® 売上予測:中期
    • KADCYLA® 売上予測:長期
  • CDX-011/ Glembatumumab Vedotin (Celldex Therapeutics)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • CDX-011の競合
    • CDX-011売上予測:長期
  • RG7599/ Lifastuzumab Vedotin (Roche / Genentech)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • RG7599の競合
    • RG7599売上予測:長期
  • BT-062 /Indatuximab Ravtansine (Biotest)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • BT-062の競合
    • BT-062売上予測:長期
  • PSMA-ADC (Progenics Pharmaceuticals)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • PSMA ADCの競合
    • PSMA ADC売上予測:長期
  • MM-302 (Merrimack Pharmaceuticals)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • MM-302の競合
    • MM-302売上予測:長期
  • IMMU-130 (Immunomedics)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • IMMU-130の競合
    • IMMU-130売上予測:長期
  • CMC-544/ Inotuzumab Ozogamicin (Pfizer)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • CMC-544の競合
    • CMC-544 /Inotuzumab Ozogamicin売上予測:長期
  • RG7596/ Polatuzumab Vedotin (Roche)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • RG7596売上予測:長期
  • SAR3419/ Coltuximab Ravtansine (ImmunoGen)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • SAR3419の競合
    • SAR3419売上予測:長期
  • ABT-414 (AbbVie)
    • 薬剤の概要
    • 作用機序
    • 臨床開発
    • 主な臨床試験結果
    • ABT-414の競合
    • ABT-414売上予測:長期
  • その他の分子

第8章 提携・協力

  • 概要
    • 提携タイプ
    • 提携件数の推移
    • Seattle Genetics・ImmunoGen:もっとも活発な企業

第9章 ベンチャーキャピタルの関心

  • 概要
  • ADCへの資金供給の例
  • ベンチャーキャピタルの関心の高まり
  • 資金供給:ファンドタイプ別の分布
  • 主要企業:資金供給件数別の分布
  • もっとも活発なVC事業者/機関

第10章 企業プロファイル

  • 概要
  • ImmunoGen
  • Seattle Genetics
  • Immunomedics
  • Pfizer
  • Roche / Genentech
  • Celldex Therapeutics
  • Millennium Pharmaceuticals
  • AbbVie
  • Bayer HealthCare
  • アステラス製薬/Agensys
  • Progenics Pharmaceuticals
  • Mersana Therapeutics
  • Synthon
  • Heidelberg Pharma
  • Oxford BioTherapeutics

第11章 ADC受託製造の例

  • 背景
  • ADC薬剤:限られた技術プロバイダー
  • ADCの製造:主要段階
  • ADCの製造:主要課題
  • ADCの社内製造
  • 世界の受託製造業者のプレゼンス
  • 投資の確実な展望
  • スタートアップ企業の出現
  • 受託製造業者の提携、など

第12章 SWOT分析

第13章 専門家へのインタビュー

第14章 総論

第15章 付録1:表データ

第16章 付録2:企業・組織リスト

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10052

The ADC market is being driven by the sales of ADCETRIS® and KADCYLA®, the only two commercially available drugs. It is a relatively new concept with respect to technology, although the individual molecules that form ADCs have been used since long. This new class of therapeutics has witnessed a strong acceptance from both big and small pharmaceutical companies as they try to fill gaps in their respective oncology pipelines. There has been a healthy growth in the number of pipeline molecules (both clinical and preclinical), suggesting a heavy focus of stakeholders in the industry. Majority of the drugs are being developed for oncological indications. In fact, several molecules are designed to target a large bandwidth of cancers, focussing on multiple indications; such molecules form 19% of the clinical pipeline.

The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Technology licensing is the preferred model for ADC development. Seattle Genetics and ImmunoGen, the two leading technology developers, have been involved in a number of partnerships. In fact, asignificant proportion of ADCs in development are based on the ADC technology of these two companies.

The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Over 80 instances of funding (equity + debt) were traced during our research, with the total investment amounting to an encouraging sum of USD 1.9 billion over the last decade. In addition to the venture capital firms, big pharma companies have also made strategic investment in smaller companies focused on developing ADCs.

A rich pipeline, promising safety / efficacy results and strong backing by venture capital firms is likely to result in a significant growth in the market over the next ten years. In the longer term, several start-ups / university spin-offs, which currently have molecules in preclinical / discovery phase, are expected to sustain the growth momentum.

Synopsis

The "Antibody Drug Conjugates Market (3rd edition), 2015-2025 " report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of ADCs. The ADC market has been one of the most actively evolving markets over the last few years and encompasses a myriad of therapies that can be potentially exploited for a broad range of cancer indications.

One of the key objectives of the study is to review and quantify the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With two marketed drugs (ADCETRIS® and KADCYLA®), the market is treading its way towards fulfilling a huge untapped promise. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
  • Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs
  • Recent partnerships that have taken place over the last decade including product co-development, licensing and clinical trial collaborations
  • Various investments and grants received by the companies focused in this area
  • Therapeutic areas forming the current focus of developers, the gradual drift and expansion towards broader application areas
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential, based on target consumer segments, likely adoption rate and expected pricing, of molecules in late stages of development

The base year for the report is 2015. The report provides market forecast for the period 2015-2025. The research, analysis and insights presented in this report include potential sales of several ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry's evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1.Driven by the sales of ADCETRIS® and KADCYLA® (the only two drugs currently available commercially), the ADC market is estimated to be worth around USD 0.9 billion in 2015.
  • 2.The market has a strong clinical pipeline of 53 molecules; nearly one-third of the molecules are in Phase II or Phase III of development. The dynamic pipeline also includes a number of molecules in preclinical/ discovery stage; in our research, we came across over 60 such molecules.
  • 3.Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
  • 4.Roche, with six molecules in clinical development, has the most developed pipeline of ADCs. Other established players in the market are (in alphabetical order) AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, GSK, Novartis, Pfizer and Sanofi.
  • 5.Relative new entrants include (in alphabetical order) AbGenomics, Allozyne, Ambrx, Biotest, Celldex Therapeutics, Centrose, CytomX Therapeutics, Esperance Pharmaceuticals, Formation Biologics, Genmab, Heidelberg Pharma, Igenica, Immunomedics, Oxford BioTherapeutics, Kairos Therapeutics, Merrimack Pharmaceuticals, Mersana Therapeutics, NBE Therapeutics, Philochem, PhotoBiotics, Progenics Pharmaceuticals, Sorrento Therapeutics, Stem CentRx, Sutro Biopharma, Synthon, Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
  • 6.About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
  • 7.Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.
  • 8.With around 10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2025.Favourable market environment and regulatory regimes could result in an even steeper growth.

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the ADC market is headed in the mid-long term.

Chapter 3 provides a general introduction to the ADCs. In this section, we have discussed, in detail, the concept of ADC, its components, mechanism of action and advantages over traditional therapies.

Chapter 4 provides a comprehensive landscape of the ADC market. This chapter has information on all the ADC molecules in development (clinical and preclinical) along with their current phase of development, key targeted indications, companies that are active in the field of ADC and most common types of cytotoxins and linkers used for ADC development.

Chapter 5 provides our analysis of the key opinion leaders (KOLs) focused in the ADC research sector. It provides a comprehensive list of principal investigators, along with their respective research institutes, and highlights KOLs who have relatively more experience.

Chapter 6 provides a competitive portfolio of various therapies being developed for the treatment of commonly targeted indications. These indications have been the prime focus of companies developing ADCs. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.

Chapter 7 presents our analysis on the ADC market opportunity in the upcoming decade. It includes detailed drug profiles and likely sales forecast for drugs currently in phase II or higher stage of development. The profiles cover information such as drug's mechanism of action, history of development, clinical trial timeline, clinical trial results, manufacturing, estimated cost of treatment and dosage regimen.

Chapter 8 provides a comprehensive list of partnerships, including the details of agreements, which have taken place between various companies over the last few years.

Chapter 9 provides information on several funding instances that have driven research and development in the field of ADCs. Our analysis reveals interesting insights on the growing interest of venture capitalists and other stakeholders in this market.

Chapter 10 includes profiles of the key companies focused in the ADC market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline ADC drugs and recent collaborations.

Chapter 11 presents a case study on ADC manufacturing. The case study discusses the current manufacturing challenges associated with ADCs and provides information on the leading contract manufacturers that are focused in this domain.

Chapter 12 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC market, capturing the key elements likely to influence future growth.

Chapter 13 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends in the market. The companies interviewed include Piramal Healthcare, Pierre Fabre, PolyTherics, Oxford BioTherapeutics, Lonza, Catalent Pharma Solutions and BSP Pharmaceuticals. Two additional companies that were interviewed requested the details to be published as anonymous.

Chapter 14 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which lists down all the companies and organisations involved in the ADC market.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Evolution of Cancer Treatment
  • 3.3. Cancer Treatment Methods
    • 3.3.1. Surgery
    • 3.3.2. Radiation Therapy
    • 3.3.3. Chemotherapy
    • 3.3.4. Targeted Therapies
  • 3.4. Monoclonal Antibodies to Treat Cancer
  • 3.5. ADCs: Essential Components
    • 3.5.1. Antibody
    • 3.5.2. Cytotoxin
    • 3.5.3. Linker
  • 3.6. Advantages of ADCs Over Traditional Therapeutics

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Clinical Pipeline
    • 4.2.1. Distribution by Phases of Development
    • 4.2.2. Distribution by Indications
    • 4.2.3. Distribution by Linkers
    • 4.2.4. Distribution by Cytotoxins
    • 4.2.5. Distribution by Technology Providers
  • 4.3. Preclinical Pipeline
    • 4.3.1. Distribution by Phases of Development
    • 4.3.2. Distribution by Indications
    • 4.3.3. Distribution by Geographies

5. KOL ANALYSIS

  • 5.1. Background
  • 5.2. Current Research Landscape
    • 5.2.1. ADCETRIS®: Key Opinion Leaders
    • 5.2.2. KADCYLA®: Key Opinion Leaders
    • 5.2.3. Other ADCs: Key Opinion Leaders
  • 5.3. Most Prominent Key Opinion Leaders

6. KEY THERAPEUTIC AREAS FOR ADCS

  • 6.1. Chapter Overview
  • 6.2. Haematological Malignancies
    • 6.2.1. Leukaemia and Lymphoma
      • 6.2.1.1. Introduction and Epidemiology: Leukaemia
        • 6.2.1.1.1. Acute Myeloid Leukaemia (AML)
        • 6.2.1.1.2. Chronic Myeloid Leukaemia (CML)
        • 6.2.1.1.3. Acute Lymphocytic Leukaemia (ALL)
        • 6.2.1.1.4. Chronic Lymphocytic Leukaemia (CLL)
      • 6.2.1.2. Introduction and Epidemiology: Lymphoma
      • 6.2.1.3. Current Treatment Landscape
        • 6.2.1.3.1. Targeted Therapies
      • 6.2.1.4. ADCs for Leukaemia/Lymphoma
    • 6.2.2. Multiple Myeloma
      • 6.2.2.1. Introduction and Epidemiology
      • 6.2.2.2. Current Treatment Landscape
      • 6.2.2.3. ADCs for Multiple Myeloma
  • 6.3. Solid Tumours
    • 6.3.1. Metastatic Melanoma
      • 6.3.1.1. Introduction and Epidemiology
      • 6.3.1.2. Current Treatment Landscape
      • 6.3.1.3. ADCs for Metastatic Melanoma
    • 6.3.2. Bladder Cancer
      • 6.3.2.1. Introduction and Epidemiology
      • 6.3.2.2. Current Treatment Landscape
      • 6.3.2.3. ADCs For Bladder Cancer
    • 6.3.3. Kidney Cancer
      • 6.3.3.1. Introduction and Epidemiology
      • 6.3.3.2. Current Treatment Landscape
      • 6.3.3.3. ADCs for Kidney Cancer
    • 6.3.4. Ovarian Cancer
      • 6.3.4.1. Introduction and Epidemiology
      • 6.3.4.2. Current Treatment Landscape
      • 6.3.4.3. ADCs for Ovarian Cancer
    • 6.3.5. Breast Cancer
      • 6.3.5.1. Introduction and Epidemiology
      • 6.3.5.2. Current Treatment Landscape
      • 6.3.5.3. ADCs for Breast Cancer
    • 6.3.6. Glioblastoma
      • 6.3.6.1. Introduction and Epidemiology
      • 6.3.6.2. Current Treatment Landscape
      • 6.3.6.3. ADCs for Glioblastoma
    • 6.3.7. Lung Cancer
      • 6.3.7.1. Introduction and Epidemiology
      • 6.3.7.2. Current Treatment Landscape
      • 6.3.7.3. ADCs for Lung Cancer
    • 6.3.8. Colorectal Cancer
      • 6.3.8.1. Introduction and Epidemiology
      • 6.3.8.2. Current Market Landscape
      • 6.3.8.3. ADCs for Colorectal Cancer
    • 6.3.9. Prostate Cancer
      • 6.3.9.1. Introduction and Epidemiology
      • 6.3.9.2. Current Market Landscape
      • 6.3.9.3. ADCs for Prostate Cancer

7. UPCOMING ADC DRUGS: DETAILED PROFILES AND MARKET FORECAST

  • 7.1. Chapter Overview
  • 7.2. Overall ADC Market Forecast, 2015 - 2025
    • 7.2.1. Scope and Limitations
    • 7.2.2. Forecast Methodology
    • 7.2.3. ADC Drug Sales Market, 2015 - 2025
    • 7.2.3.1. Overall Sales Forecast, 2015 - 2025: By Type of ADC
    • 7.2.3.1. Overall Sales Forecast, 2015 - 2025: By Type of Linker
    • 7.2.3.2. Overall Sales Forecast, 2015 - 2025: By Type of Cytotoxin
  • 7.3. ADCETRIS®/ Brentuximab vedotin (Seattle Genetics / Millennium Pharmaceuticals)
    • 7.3.1. Drug Overview
    • 7.3.2. Mechanism of Action
    • 7.3.3. Cost, Dosage and Reimbursement of ADCETRIS®
    • 7.3.4. Factors Supporting the High Price
    • 7.3.5. Clinical Development
    • 7.3.6. Key Clinical Trial Results
    • 7.3.7. ADCETRIS® Sales, 2011- H1 2015
    • 7.3.8. Strategies for Market Expansion
    • 7.3.9. ADCETRIS® Sales Forecast: Short-Midterm
    • 7.3.10. ADCETRIS® Sales Forecast: Long Term
  • 7.4. KADCYLA® / T-DM1 / RG3502 (Genentech / Roche)
    • 7.4.1. Drug Overview
    • 7.4.2. Mechanism of Action
    • 7.4.3. Cost, Dosage and Reimbursement of KADCYLA®
    • 7.4.4. Approval History
    • 7.4.5. Clinical Development
    • 7.4.6. KADCYLA® Sales, 2013 - H1, 2015
    • 7.4.7. KADCYLA® Sales Forecast: Short-Midterm
    • 7.4.8. KADCYLA® Sales Forecast: Long Term
  • 7.5. CDX-011/ Glembatumumab Vedotin (Celldex Therapeutics)
    • 7.5.1. Drug Overview
    • 7.5.2. Mechanism of Action
    • 7.5.3. Clinical Development
    • 7.5.4. Key Clinical Trial Results
    • 7.5.5. Competition for CDX-011
    • 7.5.6. CDX-011 Sales Forecast: Long Term
  • 7.6. RG7599/ Lifastuzumab Vedotin (Roche / Genentech)
    • 7.6.1. Drug Overview
    • 7.6.2. Mechanism of Action
    • 7.6.3. Clinical Development
    • 7.6.4. Key Clinical Trial Results
    • 7.6.5. Competition For RG7599
    • 7.6.6. RG7599 Sales Forecast: Long Term
  • 7.7. BT-062 /Indatuximab Ravtansine (Biotest)
    • 7.7.1. Drug Overview
    • 7.7.2. Mechanism of Action
    • 7.7.3. Clinical Development
    • 7.7.4. Key Clinical Trial Results
    • 7.7.5. Competition for BT-062
    • 7.7.6. BT-062 Sales Forecast: Long Term
  • 7.8. PSMA-ADC (Progenics Pharmaceuticals)
    • 7.8.1. Drug Overview
    • 7.8.2. Mechanism of Action
    • 7.8.3. Clinical Development
    • 7.8.4. Key Clinical Trial Results
    • 7.8.5. Competition for PSMA ADC
    • 7.8.6. PSMA ADC Sales Forecast: Long Term
  • 7.9. MM-302 (Merrimack Pharmaceuticals)
    • 7.9.1. Drug Overview
    • 7.9.2. Mechanism of Action
    • 7.9.3. Clinical Development
    • 7.9.4. Key Clinical Trial Results
    • 7.9.5. Competition for MM-302
    • 7.9.6. MM-302 Sales Forecast: Long Term
  • 7.10. IMMU-130 (Immunomedics)
    • 7.10.1. Drug Overview
    • 7.10.2. Mechanism of Action
    • 7.10.3. Clinical Development
    • 7.10.4. Key Clinical Trial Results
    • 7.10.5. Competition for IMMU-130
    • 7.10.6. IMMU-130 Sales Forecast: Long Term
  • 7.11. CMC-544/ Inotuzumab Ozogamicin (Pfizer)
    • 7.11.1. Drug Overview
    • 7.11.2. Mechanism of Action
    • 7.11.3. Clinical Development
    • 7.11.4. Key Clinical Trial results
    • 7.11.5. Competition for CMC-544
    • 7.11.6. CMC-544 /Inotuzumab Ozogamicin Sales Forecast: Long Term, 2019-2025
  • 7.12. RG7596/ Polatuzumab Vedotin (Roche)
    • 7.12.1. Drug Overview
    • 7.12.2. Mechanism of Action
    • 7.12.3. Clinical Development
    • 7.12.4. Key Clinical Trial Results
    • 7.12.5. RG7596 Sales Forecast: Long Term
  • 7.13. SAR3419/ Coltuximab Ravtansine (ImmunoGen)
    • 7.13.1. Drug Overview
    • 7.13.2. Mechanism of Action
    • 7.13.3. Clinical Development
    • 7.13.4. Key Clinical Trial Results
    • 7.13.5. Competition for SAR3419
    • 7.13.6. SAR3419 Sales Forecast: Long Term
  • 7.14. ABT-414 (AbbVie)
    • 7.14.1. Drug Overview
    • 7.14.2. Mechanism of Action
    • 7.14.3. Clinical Development
    • 7.14.4. Key Clinical Trial Results
    • 7.14.5. Competition for ABT-414
    • 7.14.6. ABT-414 Sales Forecast: Long Term
  • 7.15. Other Molecules

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
    • 8.1.1. Type of Partnerships
    • 8.1.2. Number of Partnerships have Increased Overtime
    • 8.1.3. Seattle Genetics and ImmunoGen have been the Most Active Companies

9. VENTURE CAPITAL INTEREST

  • 9.1. Chapter Overview
  • 9.2. Instances of Funding in ADCs
  • 9.3. Rising Venture Capital Interest
  • 9.4. Funding Instances: Distribution by Type of Funding
  • 9.5. Leading Players: Distribution by Number of Funding Instances
  • 9.6. Most Active VC Firms/Institutions

10. COMPANY PROFILES

  • 10.1. Chapter Overview
  • 10.2. ImmunoGen
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. ADC Pipeline
    • 10.2.4. Collaborations
  • 10.3. Seattle Genetics
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. ADC Pipeline
    • 10.3.4. Collaborations
  • 10.4. Immunomedics
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. ADC Pipeline
    • 10.4.4. Collaborations
  • 10.5. Pfizer
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. ADC Pipeline
    • 10.5.4. Collaborations
  • 10.6. Roche / Genentech
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. ADC Pipeline
    • 10.6.4. Collaborations
  • 10.7. Celldex Therapeutics
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. ADC Pipeline
    • 10.7.4. Collaborations
  • 10.8. Millennium Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. ADC Pipeline
    • 10.8.4. Collaborations
  • 10.9. AbbVie
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. ADC Pipeline
    • 10.9.4. Recent Developments
    • 10.9.5. Collaborations
  • 10.11. Bayer HealthCare
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. ADC Pipeline
    • 10.11.4. Collaborations
  • 10.12. Astellas Pharma/Agensys
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. ADC Pipeline
    • 10.12.4. Collaborations
  • 10.13. Progenics Pharmaceuticals
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. ADC Pipeline
    • 10.13.4. Collaborations
  • 10.14. Mersana Therapeutics
    • 10.14.1. Company Overview
    • 10.14.2. ADC Pipeline
    • 10.14.3. Collaborations
  • 10.15. Synthon
    • 10.15.1. Company Overview
    • 10.15.2. ADC Pipeline
    • 10.15.3. Collaborations
  • 10.16. Heidelberg Pharma
    • 10.16.1. Company Overview
    • 10.16.2. ADC Pipeline
    • 10.16.3. Collaborations
  • 10.17. Oxford BioTherapeutics
    • 10.17.1. Company Overview
    • 10.17.2. ADC Pipeline
    • 10.17.3. Collaborations

11. CASE IN POINT: CONTRACT MANUFACTURING IN ADCs

  • 11.1. Background
  • 11.2. ADC Drugs: Limited Technology Providers
  • 11.3. ADC Manufacturing: Key Steps
  • 11.4. ADC Manufacturing: Key Challenges
  • 11.5. In-House Manufacturing of ADCs
  • 11.6. Global Presence of Contract Manufacturers
  • 11.7. A Promising Scope For Investment
  • 11.8. Emergence of Start-Ups
  • 11.9. Contract Manufacturers Collaborating to Provide ADC Capabilities
  • 11.10. CMOs Manufacturing Linkers
  • 11.11. CMOs with HPAPI / Cytotoxic Capabilities
  • 11.12. Growing Conjugation Capability
  • 11.13. Full Service Providers for ADCs: An Unmet Need

12. SWOT ANALYSIS

  • 12.1. Strengths
  • 12.2. Weaknesses
  • 12.3. Opportunities
  • 12.4. Threats

13. INTERVIEW TRANSCRIPTS

  • 13.1. Chapter Overview
  • 13.2. Interview 1: Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • 13.3. Interview 2: Christian Bailly, Head of CDMO, Pierre Fabre
  • 13.4. Interview 3: Dr. John Burt, CEO, PolyTherics (an Abzena company)
  • 13.5. Interview 4: Christian Rohlff, Founder & CEO, Oxford BioTherapeutics
  • 13.6. Interview 5: Laurent Ducry, ADC R&D, Lonza
  • 13.7. Interview 6: Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development, Catalent Pharma Solutions
  • 13.8. Interview 7: Aldo Braca, CEO, BSP Pharmaceuticals
  • 13.9. Interview 8: Director, Business Development, Anonymous CMO
  • 13.10. Interview 9: Chief Executive Officer, Anonymous CMO

14. CONCLUSION

  • 14.1. ADCETRIS® and KADCYLA®: The Current Flagbearers
  • 14.2. Several Molecules Likely to Achieve Blockbuster Status
  • 14.3. CMOs Expected to Play a Critical Role in Future Success
  • 14.4. An Attractive Market for Large Pharmaceutical Companies; Start-ups Continue to Emerge
  • 14.5. Collaborations Have Been Widespread; The Trend is Unlikely to Change
  • 14.6. Concluding Remarks

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

  • Figure 3.1 Timeline of Cancer Treatments
  • Figure 3.2 Cancer Treatments: Type of Surgeries
  • Figure 3.3 Cancer Treatments: Type of Radiation Therapies
  • Figure 3.4 Cancer Treatments: Type of Chemotherapies
  • Figure 3.5 Components of ADC
  • Figure 4.1 ADC Clinical Pipeline: Distribution by Phases of Development
  • Figure 4.2 ADC Clinical Pipeline: Distribution by Indications
  • Figure 4.3 ADC Clinical Pipeline: Distribution by Linkers
  • Figure 4.4 ADC Clinical Pipeline: Distribution by Cytotoxins
  • Figure 4.5 ADC Clinical Pipeline: Distribution by Technology Providers
  • Figure 4.6 ADC Preclinical / Discovery Pipeline: Distribution by Phases of Development
  • Figure 4.7 ADC Preclinical Pipeline: Distribution by Indications
  • Figure 4.9 ADC Preclinical Pipeline: Distribution by Geographies
  • Figure 5.1 ADCETRIS®: Mapping Prominent Researchers
  • Figure 5.2 KADCYLA®: Mapping Prominent Researchers
  • Figure 5.3 Other ADCs: Mapping Prominent Researchers
  • Figure 5.4 ADC: Prominent Key Opinion Leaders
  • Figure 6.1 Most Common Types of Leukaemia
  • Figure 6.2 Leukaemia: Global Epidemiological Distribution
  • Figure 6.3 Lymphoma: Global Epidemiological Distribution
  • Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
  • Figure 6.5 Melanoma: Global Epidemiological Distribution
  • Figure 6.6 Bladder Cancer: Global Epidemiological Distribution
  • Figure 6.7 Kidney Cancer: Global Epidemiological Distribution
  • Figure 6.8 Ovarian Cancer: Global Epidemiological Distribution
  • Figure 6.9 Breast Cancer: Global Epidemiological Distribution
  • Figure 6.10 Lung Cancer: Types
  • Figure 6.11 Lung Cancer: Global Epidemiological Distribution
  • Figure 6.12 Colorectal Cancer: Global Epidemiological Distribution
  • Figure 6.13 Prostate Cancer: Global Epidemiological Distribution
  • Figure 7.1 ADC Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
  • Figure 7.2 ADC Sales Forecast, 2015 - 2025: By Type of ADC (USD Million)
  • Figure 7.3 ADC Sales Forecast, 2015 - 2025: By Type of Linker (USD Million)
  • Figure 7.4 ADC Sales Forecast, 2015 - 2025: By Type of Cytotoxin (USD Million)
  • Figure 7.5 ADCETRIS®: Registered Clinical Trials
  • Figure 7.6 ADCETRIS® Sales: 2011 - H1, 2015 (USD Million)
  • Figure 7.7 ADCETRIS® Market (USD Million), Short-Midterm Forecast: (Base Scenario)
  • Figure 7.8 ADCETRIS® Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.9 KADCYLA®: Registered Clinical Trials
  • Figure 7.10 KADCYLA® Sales, 2013 - H1, 2015 (CHF Million)
  • Figure 7.11 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: (Base Scenario)
  • Figure 7.12 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.13 CDX-011: Registered Clinical Trials
  • Figure 7.14 CDX-011/ Glembatumumab Vedotin Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.15 RG7599: Registered Clinical Trials
  • Figure 7.16 RG7599 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.17 BT-062 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.18 PSMA-ADC: Registered Clinical Trials
  • Figure 7.19 PSMA ADC Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.20 MM-302 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.21 IMMU-130: Registered Clinical trials
  • Figure 7.22 IMMU-130 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.23 CMC-544: Registered Clinical Trials
  • Figure 7.24 CMC-544/ Inotuzumab Ozogamicin Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.25 RG7596: Registered Clinical Trials
  • Figure 7.26 RG7596 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.27 SAR3419: Registered Clinical Trials
  • Figure 7.28 SAR3419 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.29 ABT-414 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.30 BAY94-9343 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 7.31 IMMU-132 Market (USD Million), Long Term Forecast: (Base Scenario)
  • Figure 8.1 ADC: Partnerships, 2005 - 2015
  • Figure 8.2 ADC Partnerships: Major Stakeholders
  • Figure 9.1 Cumulative Funding Instances, Pre 2005 - 2015
  • Figure 9.2 Funding Instances: Total Amount Invested Annually (USD Million)
  • Figure 9.3 Funding Instances: Distribution by Type, Pre 2005 - 2015
  • Figure 9.4 Funding Instances: Distribution by Total Amount Invested, (USD Million)
  • Figure 9.5 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.6 Most Active VC Firms: Evaluation by Number of Instances
  • Figure 10.1 ImmunoGen: Revenues (USD Million), 2011 - 2015
  • Figure 10.2 Seattle Genetics: Revenues (USD Million), 2010 - H1 2015
  • Figure 10.3 Immunomedics: Revenues (USD Million), 2011 - 2015
  • Figure 10.4 Pfizer: Revenues (USD Billion), 2010 - H1, 2015
  • Figure 10.5 Roche: Revenues (CHF Billion), 2011 - H1, 2015
  • Figure 10.6 Roche: Segment Sales (CHF Billion), 2010 - H1, 2015
  • Figure 10.7 Celldex Therapeutics: Revenues (USD Million), 2010 - H1, 2015
  • Figure 10.8 Takeda Pharmaceuticals: Revenues (JPY Billion), 2010 - 2014
  • Figure 10.9 AbbVie: Revenues (USD Billion), 2010 - Q3, 2015
  • Figure 10.10 Bayer HealthCare: Revenues (EUR Billion), 2010 - Q3, 2015
  • Figure 10.11 Astellas Pharma: Revenues (JPY Billion), 2011 - 2015
  • Figure 10.12 Progenics Pharmaceuticals: Revenues (USD Million), 2010 - 2014
  • Figure 11.1 ADC Market Forecast (USD Million): 2015, 2020 and 2025

List of Tables

  • Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
  • Table 3.2 Commonly Used Cytotoxins for ADC Therapeutics
  • Table 3.3 OEL Bands, Safebridge Consultants
  • Table 4.1 ADCs: Marketed and Development Pipeline
  • Table 4.2 ADCs: Preclinical Pipeline
  • Table 5.1 ADCs: Principal Investigators
  • Table 6.1 Comparison of HL and NHL
  • Table 6.2 Comparison of Marketed Targeted Therapeutics: Leukaemia
  • Table 6.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
  • Table 6.4 ADCs for Leukaemia and Lymphoma
  • Table 6.5 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
  • Table 6.6 ADCs for Multiple Myeloma
  • Table 6.7 Comparison of Marketed Targeted Therapeutics: Melanoma
  • Table 6.8 ADCs for Metastatic Melanoma
  • Table 6.9 ADCs for Bladder Cancer
  • Table 6.10 Comparison of Marketed Targeted Therapeutics: RCC
  • Table 6.11 ADCs for Kidney Cancer
  • Table 6.12 ADCs for Ovarian Cancer
  • Table 6.13 Comparison of Marketed Therapeutics: Breast Cancer
  • Table 6.14 ADCs for Breast Cancer
  • Table 6.15 ADCs for Glioblastoma
  • Table 6.16 Comparison of Marketed Therapeutics: Lung Cancer
  • Table 6.17 ADCs for Lung Cancer
  • Table 6.18 Comparison of Marketed Therapeutics: Colorectal Cancer
  • Table 6.19 ADCs for Colorectal Cancer
  • Table 6.20 Comparison of Marketed Therapeutics: Prostate Cancer
  • Table 6.21 ADCs for Prostate Cancer
  • Table 7.1 ADCs: Marketed/ Late Stage Molecules
  • Table 7.2 ADCETRIS®/ Brentuximab vedotin: Ongoing Clinical Trials
  • Table 7.3 KADCYLA® / T-DM1: Ongoing Clinical Trials
  • Table 7.4 CDX-011/ Glembatumumab Vedotin: Ongoing Clinical Trials
  • Table 7.5 RG7599/ Lifastuzumab Vedotin: Ongoing Clinical Trials
  • Table 7.6 BT-062: Ongoing Clinical Trials
  • Table 7.7 Comparison of Drugs Available for Metastatic Castration Resistant Prostate Cancer
  • Table 7.8 MM-302: Ongoing Clinical Trials
  • Table 7.9 IMMU-130: Ongoing Clinical Trials
  • Table 7.10 CMC-544/ Inotuzumab Ozogamicin: Ongoing Clinical Trials
  • Table 7.11 RG7596/ Polatuzumab Vedotin: Ongoing Clinical Trials
  • Table 7.12 SAR3419/ Coltuximab Ravtansine: Ongoing Clinical Trials
  • Table 7.13 ABT-414: Ongoing Clinical Trials
  • Table 8.1 List of Partnerships in the Field of ADCs, 2000 - 2015
  • Table 9.1 List of Funding Instances in ADCs
  • Table 9.2 Types of Funding Instances, 1998-2015
  • Table 10.1 ImmunoGen ADC Pipeline, 2015
  • Table 10.2 Seattle Genetics ADC Pipeline, 2015
  • Table 10.3 Immunomedics ADC Pipeline, 2015
  • Table 10.4 Pfizer / Wyeth ADC Pipeline, 2015
  • Table 10.5 Roche / Genentech ADC Pipeline, 2015
  • Table 10.6 Celldex Therapeutics ADC Pipeline, 2015
  • Table 10.7 Millennium Pharmaceuticals ADC Pipeline, 2015
  • Table 10.8 AbbVie ADC Pipeline, 2015
  • Table 10.9 Bayer HealthCare ADC Pipeline, 2015
  • Table 10.12 Mersana Therapeutics ADC Pipeline, 2015
  • Table 11.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
  • Table 11.2 CMOs Offering ADC Conjugation Services
  • Table 11.3 Full Service Contract Manufacturers for ADCs
  • Table 9.1 SWOT Analysis
  • Table 15.1 ADC Clinical Pipeline: Distribution by Phases of Development
  • Table 15.2 ADC Clinical Pipeline: Distribution by Indications
  • Table 15.3 ADC Clinical Pipeline: Distribution by Linkers
  • Table 15.4 ADC Clinical Pipeline: Distribution by Cytotoxins
  • Table 15.5 ADC Clinical Pipeline: Distribution by Technology Developers
  • Table 15.6 ADC Preclinical / Discovery Pipeline: Distribution by Phases of Development
  • Table 15.7 ADC Preclinical / Discovery Pipeline: Distribution by Indications
  • Table 15.8 ADC Preclinical / Discovery Pipeline: Distribution by Geographies
  • Table 15.9 ADC Sales Forecast, 2015- 2025: Conservative Scenario (USD Million)
  • Table 15.10 ADC Sales Market Forecast, 2015- 2025: Base Scenario (USD Million)
  • Table 15.11 ADC Sales Market Forecast, 2015-2025: Optimistic Scenario (USD Million)
  • Table 15.12 ADC Sales Forecast by Type of ADCs, 2015-2025: Conservative Scenario (USD Million)
  • Table 15.13 ADC Sales Forecast by Type of ADCs 2015-2025: Base Scenario (USD Million)
  • Table 15.14 ADC Sales Forecast by Type of ADCs 2015-2025: Optimistic Scenario (USD Million)
  • Table 15.15 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Conservative Scenario (USD Million)
  • Table 15.16 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Base Scenario (USD Million)
  • Table 15.17 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Optimistic Scenario (USD Million)
  • Table 15.18 ADC Sales Forecast by Type of Linker (2015-2025): Conservative Scenario (USD Million)
  • Table 15.19 ADC Sales Forecast by Type of Linker (2015-2025): Base Scenario (USD Million)
  • Table 15.20 ADC Sales Forecast by Type of Linker (2015-2025): Optimistic Scenario (USD Million)
  • Table 15.21 ADCETRIS®: Registered Clinical Trials
  • Table 15.22 ADCETRIS® Market (USD Million), Short-Midterm Forecast: Conservative Scenario
  • Table 15.23 ADCETRIS® Market (USD Million), Short-Midterm Forecast:Base Scenario
  • Table 15.24 ADCETRIS® Market (USD Million), Short-Midterm Forecast:Optimistic Scenario
  • Table 15.25 ADCETRIS® Market (USD Million), Long Term Forecast:Conservative Scenario
  • Table 15.26 ADCETRIS® Market (USD Million), Long Term Forecast:Base Scenario
  • Table 15.27 ADCETRIS® Market (USD Million), Long Term Forecast:Optimistic Scenario
  • Table 15.28 KADCYLA®: Registered Clinical Trials
  • Table 15.29 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Conservative Scenario
  • Table 15.30 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Base Scenario
  • Table 15.31 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Optimistic Scenario
  • Table 15.32 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.33 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.34 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.35 CDX-011: Registered Clinical Trials
  • Table 15.36 CDX-011 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.37 CDX-011 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.38 CDX-011 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.39 RG7599: Registered Clinical Trials
  • Table 15.40 RG7599 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.41 RG7599 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.42 RG7599 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.43 BT-062 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.44 BT-062 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.45 BT-062 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.46 PSMA ADC: Registered Clinical Trials
  • Table 15.47 PSMA ADC Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.48 PSMA ADC Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.49 PSMA ADC Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.50 MM-302 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.51 MM-302 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.52 MM-302 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.53 IMMU-130: Registered Clinical Trials
  • Table 15.54 IMMU-130 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.55 IMMU-130 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.56 IMMU-130 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.57 CMC-544: Registered Clinical Trials
  • Table 15.58 CMC-544 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.59 CMC-544 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.60 CMC-544 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.61 RG7596: Registered Clinical Trials
  • Table 15.62 RG7596 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.63 RG7596 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.64 RG7596 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.65 SAR 3419: Registered Clinical Trials
  • Table 15.66 SAR 3419 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.67 SAR 3419 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.57 SAR 3419 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.69 ABT-414 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.70 ABT-414 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.71 ABT-414 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.72 BAY949343 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.73 BAY949343 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.74 BAY949343 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.75 IMMU132 Market (USD Million), Long Term Forecast: Conservative Scenario
  • Table 15.76 IMMU132 Market (USD Million), Long Term Forecast: Base Scenario
  • Table 15.77 IMMU132 Market (USD Million), Long Term Forecast: Optimistic Scenario
  • Table 15.78 ADC: Partnerships, 2005-2015
  • Table 15.79 ADC Partnerships: Major Stakeholders
  • Table 15.80 Funding: Cumulative Number of Investments by Year, 1998-2015
  • Table 15.81 Funding Instances: Total Amount Invested Annually (USD Million)
  • Table 15.82 Funding Instances: Distribution by Type, 1998-2015
  • Table 15.83 Funding Instances: Distribution by Total Amount Invested, 1998-2015
  • Table 15.84 Most Active Players: Distribution by Number Funding Instances
  • Table 15.85 Most Active VC Firms: Evaluation by Number Funding Instances
  • Table 15.86 ImmunoGen: Revenues (USD Million), 2011-2015
  • Table 15.87 Seattle Genetics: Revenues (USD Million), 2010-H1, 2015
  • Table 15.88 Immunomedics: Revenues (USD Million), 2011- 2015
  • Table 15.89 Pfizer: Revenues (USD Billion), 2010- H1, 2015
  • Table 15.90 Roche: Revenues (CHF Billion), 2010- H1, 2015
  • Table 15.91 Roche: Segment Revenues (CHF Billion), 2010-H1, 2015
  • Table 15.92 Celldex Therapeutics: Revenues (USD Billion), 2010- H1, 2015
  • Table 15.93 Takeda Pharmaceuticals (JPY Billion): Revenues, 2010- 2014
  • Table 15.94 AbbVie: Revenues (USD Billion), 2010- Q3, 2015
  • Table 15.95 Bayer HealthCare: Revenues (EUR Billion), 2010- Q3, 2015
  • Table 15.96 Astellas Pharma: Revenues (JPY Billion), 2011- 2015
  • Table 15.97 Progenics Pharmaceuticals: Revenues (USD Million), 2010- 2014
  • Table 15.98 ADC Market Forecast (USD Million): 2015, 2020, 2025

Listed Companies

Following companies and organisations have been mentioned in this report.

  • 1. AAIPharma Services Corp
  • 2. AB SCIEX
  • 3. AbbVie
  • 4. AbGenomics
  • 5. Abramson Cancer Center of the University of Pennsylvania
  • 6. Abraxis BioScience
  • 7. Academic and Community Cancer Research United
  • 8. Academic Medical Center, University of Amsterdam
  • 9. ACES Pharma
  • 10. ADC Therapeutics
  • 11. Adimab
  • 12. Affinity Lifesciences
  • 13. Agensys
  • 14. AIDS Malignancy Consortium
  • 15. Algeta
  • 16. Allos Therapeutics
  • 17. Allozyne
  • 18. ALMAC Group
  • 19. Ambrx
  • 20. American Cancer Society
  • 21. American Society of Clinical Oncology (ASCO)
  • 22. American Society of Haematology, San Francisco
  • 23. AmerisourceBergen Corporation
  • 24. Amgen
  • 25. AMRI Global
  • 26. Asan Medical Center
  • 27. Aspyrian Therapeutics
  • 28. Astellas Pharma
  • 29. AstraZeneca
  • 30. Asymchem
  • 31. Avid Biologics
  • 32. Bachem
  • 33. Barbara Ann Karmanos Cancer Institute
  • 34. Baxter BioPharma Solutions
  • 35. Bayer Healthcare
  • 36. Beatson West of Scotland Cancer Center
  • 37. BioAgilytix Labs
  • 38. Biogen Idec
  • 39. BioOutsource
  • 40. BioPharma Solutions
  • 41. Biotechnique
  • 42. Biotecnol
  • 43. Biotest
  • 44. BioWa
  • 45. Boehringer Ingelheim
  • 46. Bristol-Myers Squibb
  • 47. Brown University
  • 48. BSP Pharmaceuticals
  • 49. Cambrex Corporation
  • 50. Cancer Institute of Lorraine
  • 51. Cancer Research Technology (CRT), UK
  • 52. Cancer Research, UK
  • 53. Cancer Treatment Centers of America
  • 54. Cantonal Hospital of St. Gallen
  • 55. CARBOGEN AMCIS
  • 56. Cardinal Health
  • 57. Catalent Pharma Solution
  • 58. Celgene
  • 59. Celldex Therapeutics
  • 60. Centers for Disease Control and Prevention
  • 61. Centre Hospitalier Lyon Sud, France
  • 62. Centre Oscar Lambret
  • 63. Centrose
  • 64. ChemCon
  • 65. ChemPartner
  • 66. Children's Oncology Group
  • 67. Chu de Limoges
  • 68. Chugai Pharmaceutical
  • 69. City of Hope Medical Center
  • 70. CMC Biologics
  • 71. Coldstream Laboratories
  • 72. Columbia University
  • 73. Concortis
  • 74. Creative Biolabs
  • 75. CuraGen
  • 76. Cytogen Corporation
  • 77. CytomX Therapeutics
  • 78. Cytovance Biologics LLC
  • 79. Daiichi Sankyo
  • 80. Dalton Pharma Services
  • 81. Dana-Farber Cancer Institute
  • 82. Dendreon Corporation
  • 83. Dishman Group
  • 84. ECOG-ACRIN Cancer Research Group
  • 85. EirGenix
  • 86. Eisai
  • 87. Elder Pharmaceuticals
  • 88. Eli Lilly
  • 89. Endo Pharmaceuticals
  • 90. Endocyte
  • 91. Esperance Pharmaceuticals
  • 92. Eucodis
  • 93. European Organisation for Research and Treatment of Cancer
  • 94. Evonik
  • 95. Ferring Pharmaceuticals
  • 96. Ferro Pfanstiehl
  • 97. Fidelity Biosciences
  • 98. Formation Biologics
  • 99. Formosa Laboratories
  • 100. Fox Chase Cancer Center
  • 101. FUJIFILM Diosynth Biotechnologies
  • 102. Genentech
  • 103. General Hospital Linz
  • 104. Genmab
  • 105. Genzyme
  • 106. German Federal Ministry of Education and Research
  • 107. Gilead Sciences
  • 108. GLOBOCAN
  • 109. Goodwin Biotechnology
  • 110. GSK
  • 111. GTC Biotherapeutics
  • 112. Guys Hospital
  • 113. H. Lee Moffitt Cancer Center & Research Institute Dept of Onc
  • 114. Harris and Harris Group
  • 115. Hartmann Oncology Radiotherapy Group
  • 116. Heidelberg Pharma
  • 117. Heraeus
  • 118. Hospital Ramon y Cajal, Madrid, Spain
  • 119. Hospital Saint-Louis
  • 120. Hospital Universitario de Salamanca
  • 121. iBIOSOURCE
  • 122. ICM
  • 123. IDT Australia
  • 124. Igenica
  • 125. ImClone Systems
  • 126. Immunogen
  • 127. Immunomedics
  • 128. INC Research
  • 129. Innsbruck Medical University
  • 130. Institut Bergonié, Bordeaux
  • 131. Institut Curie
  • 132. Invenra
  • 133. IRCCS AOU San Martino
  • 134. IUHealth Goshen Center for Cancer Care
  • 135. Janssen Biotech
  • 136. Johnson & Johnson
  • 137. Jules Bordet Institute
  • 138. Kairos Therapeutics
  • 139. Karolinska university hospital
  • 140. Kemwell
  • 141. Korea Cancer Center Hospital
  • 142. Leica Biosystems
  • 143. Leukaemia and Lymphoma Society
  • 144. Life Science Pharmaceuticals
  • 145. Ligand Pharmaceuticals
  • 146. Lonza
  • 147. Lymphoma Study Association
  • 148. M D Anderson Cancer Center
  • 149. MAB Discovery
  • 150. MacroGenics
  • 151. Massachusetts General Hospital
  • 152. Mayo Clinic
  • 153. McKesson Corporation
  • 154. Medarex
  • 155. Medical College of Wisconsin
  • 156. Medical University of Vienna
  • 157. MedImmune
  • 158. Medivation
  • 159. MedStar Washington Hospital Center
  • 160. Memorial Sloan-Kettering Cancer Center
  • 161. Menarini
  • 162. Merck
  • 163. Merrimack Pharmaceuticals
  • 164. Mersana Therapeutics
  • 165. Millenium Pharmaceuticals
  • 166. MiMabs
  • 167. Molecular Insight Pharmaceuticals
  • 168. Morphotek
  • 169. Natco Pharma
  • 170. National Cancer Center of Korea
  • 171. National Cancer Institute
  • 172. National Research Council of Canada
  • 173. NBE Therapeutics
  • 174. New Enterprise Associates
  • 175. New York Medical College
  • 176. Nordic Nanovector
  • 177. Norfolk and Norwich Hospital
  • 178. Northwestern University
  • 179. Nottingham University Hospitals NHS Trust
  • 180. Novartis
  • 181. Novasep
  • 182. Novella Clinical
  • 183. NSABP Foundation
  • 184. Ohio State University
  • 185. Oncology Institute of Southern Switzerland
  • 186. Oncology-Rinat Research and Development (ORRD)
  • 187. Ono Pharmaceutical
  • 188. Onyx Pharmaceuticals
  • 189. Oslo University Hospital
  • 190. Oxford BioTherapeutics
  • 191. Pacific GMP
  • 192. Patheon
  • 193. Pfizer
  • 194. Pharmacyclics
  • 195. Philochem
  • 196. Philogen
  • 197. PhotoBiotics
  • 198. Pierre Fabre Group
  • 199. Piramal Pharma Solutions
  • 200. PolyTherics
  • 201. Princess Margaret Hospital
  • 202. Progenics Pharmaceuticals
  • 203. Project Pharmaceutics
  • 204. ProQuest Investments
  • 205. PureTech Ventures
  • 206. QPS Holdings
  • 207. Quanta BioDesign
  • 208. Queen Elizabeth Hospital
  • 209. Recepta Biopharma
  • 210. Redwood Bioscience
  • 211. Regional Center for the Fight Against Cancer
  • 212. Roche
  • 213. Royal Liverpool Hospital
  • 214. S. Orsola Malpighi
  • 215. SAFC
  • 216. SafeBridge Consultants
  • 217. Sandoz
  • 218. Sanofi
  • 219. Sarah Cannon Research Institute
  • 220. SCRI Innovations
  • 221. Seattle Genetics
  • 222. Seoul National University Hospital
  • 223. Seragon Pharmaceuticals
  • 224. Severance Hospital
  • 225. Shanghai Fosun Pharma
  • 226. Sigma-Aldrich Corporation
  • 227. Societa Italiana Corticosteroidi
  • 228. Society for Neuro-Oncology (SNO), Miami
  • 229. Sorrento Therapeutics
  • 230. Southampton General Hospital
  • 231. Southwest Oncology Group
  • 232. Spectrum Pharmaceuticals
  • 233. Spirogen
  • 234. St James University Hospital
  • 235. St. Jude Children's Research Hospital
  • 236. Stem CentRx
  • 237. Sutro Biopharma
  • 238. Symbiosis Pharmaceutical Services
  • 239. Syntarga
  • 240. Synthon
  • 241. Takeda Pharmaceutical
  • 242. The Chemistry Research Solution
  • 243. The Christie Hospital
  • 244. The Churchill Hospital,UK
  • 245. The Freeman Hospital
  • 246. The Institute of Haematology in Bologna
  • 247. The Methodist Hospital System
  • 248. Tuas Biomedical Park
  • 249. TUBE Pharma
  • 250. UCB Pharma
  • 251. UCL School of Pharmacy
  • 252. UCLA Jonsson Comprehensive Cancer Center
  • 253. Union Chimique Belge
  • 254. University Hospital of Wales
  • 255. University Hospital, UK
  • 256. University Hospitals Seidman Cancer Center
  • 257. University of Alabama
  • 258. University of Amsterdam
  • 259. University of California
  • 260. University of Cologne
  • 261. University of Kansas Medical Center Research Institute
  • 262. University of Modena and Reggio Emilia
  • 263. University of Munich
  • 264. University of Oklahoma Stephenson Cancer Center
  • 265. University of Texas Health Science Center
  • 266. University of Ulm
  • 267. University of Washington Cancer Consortium
  • 268. UT Southwestern Medical Center
  • 269. UZ Leuven Hospital
  • 270. Valeant Pharmaceutical
  • 271. Vanderbilt-Ingram Cancer Center
  • 272. Ventana Medical Systems
  • 273. Victor Hugo Surgical Clinic
  • 274. Virginia Cancer Specialists, PC
  • 275. VivaMab
  • 276. Washington University School of Medicine
  • 277. Waters
  • 278. Watson Pharmaceuticals
  • 279. Weill Medical College of Cornell University
  • 280. Western Regional Medical Center
  • 281. WILEX
  • 282. WuXi PharmaTech
  • 283. Wyeth
  • 284. Zhejiang Medicine Co. (ZMC)
  • 285. Zymeworks

Following venture capital firms / investors have been mentioned in this report.

  • 1. 5AM Ventures
  • 2. Advanced Biotechnologies Venture Fund
  • 3. Advantage Capital Partners
  • 4. Advent Venture Partners
  • 5. Alexandria Real Estate Equities
  • 6. Alta Partners
  • 7. Amgen Ventures
  • 8. Apax Partner
  • 9. Apposite Capital
  • 10. Aravis Ventures
  • 11. ARCH Venture Partners
  • 12. Auven Therapeutics
  • 13. BankInvest Group
  • 14. Bear Sterns Health Innoventures
  • 15. Boehringer Ingelheim Venture Fund
  • 16. BSI
  • 17. Canaan Partners
  • 18. Carnegie Kapitalforvaltning
  • 19. Cascade Investment
  • 20. Casdin Capital
  • 21. Catapult Ventures
  • 22. Cooley Godward Kronish
  • 23. Cormorant Asset Management
  • 24. Credit Suisse First Boston Next Fund
  • 25. Crocker Ventures
  • 26. CTI Life Sciences Fund
  • 27. Dansk Erhvervsinvestering
  • 28. Deerfield Management
  • 29. Dow Venture Capital
  • 30. Duquesne Capital Management
  • 31. Expansion Venture Capital
  • 32. Fidelity Investments
  • 33. Fred Alger Management
  • 34. Glynn Capital Management
  • 35. H&Q Life Sciences Investments
  • 36. Hambrecht & Quist Capital Management
  • 37. HBM BioVentures
  • 38. HBM Partners
  • 39. HealthCap Venture Capital
  • 40. Hercules Technology Growth Capital
  • 41. HNI Holdings
  • 42. Index Ventures
  • 43. Innovis Investments
  • 44. International Biotechnology Trust
  • 45. Iroquois Capital Group
  • 46. JAFCO
  • 47. Jennison Associates
  • 48. Lilly Ventures
  • 49. LODH Private Equity Partners
  • 50. Lombard Odier Darier Hentsch & Cie
  • 51. Maverick Capital
  • 52. Modal Capital L.P.
  • 53. MPM Capital
  • 54. MS Seed Capital
  • 55. MS Ventures
  • 56. Nextech Venture
  • 57. Noonday Asset Management
  • 58. Orbimed Advisors
  • 59. OVP Venture Partners
  • 60. Oxford Capital Partners
  • 61. Perceptive Advisors
  • 62. Pfizer Venture Investments
  • 63. Presidio Partners
  • 64. Redmile Group
  • 65. ReqMed Company
  • 66. Research Corporation Technologies
  • 67. Roche Venture Fund
  • 68. Scale Venture Partners
  • 69. Scottish Widows Investment Partnership
  • 70. Silicon Valley Bank
  • 71. Skyline Ventures
  • 72. Sofinnova Ventures
  • 73. Sorenson Development
  • 74. South East Growth Fund & Management
  • 75. Suez Ventures
  • 76. SV Life Sciences
  • 77. Tavistock Life Sciences
  • 78. Tekla Healthcare investors & Tekla Life Science Investors
  • 79. The Column Group
  • 80. Themelios Ventures
  • 81. Third Rock Ventures
  • 82. TPG-Axon Capital
  • 83. Twilight Venture Partners
  • 84. Unilever Technology Ventures Fund B.V.
  • 85. Union Carbide Employees Pension Plan
  • 86. Venrock Healthcare Capital Partners
  • 87. Venture Associates
  • 88. Ventures West Capital
  • 89. Versant Ventures
  • 90. VLG Investments
  • 91. Vulcan Capital
  • 92. Wellington Management Company
  • 93. Wharton Biotechnology Partners
  • 94. WT Investment Advisors Fund
  • 95. Ziff Asset Management
  • 96. Zroche Venture Fund
Back to Top